Edition:
United Kingdom

Karo Pharma AB (KARO.ST)

KARO.ST on Stockholm Stock Exchange

36.75SEK
5:00pm BST
Change (% chg)

-0.90kr (-2.39%)
Prev Close
37.65kr
Open
37.70kr
Day's High
37.80kr
Day's Low
36.50kr
Volume
753,084
Avg. Vol
690,762
52-wk High
41.68kr
52-wk Low
25.25kr

Chart for

About

Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company’s pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer... (more)

Overall

Beta: 0.71
Market Cap(Mil.): kr3,270.22
Shares Outstanding(Mil.): 82.17
Dividend: 0.28
Yield (%): 0.70

Financials

  KARO.ST Industry Sector
P/E (TTM): 20.39 85.69 32.76
EPS (TTM): 1.95 -- --
ROI: 11.70 1.78 14.61
ROE: 15.82 3.28 16.33

BRIEF-Karo Pharma Determines Terms For Rights Issue

* THE TERMS FOR KARO PHARMA'S RIGHTS ISSUE HAVE BEEN DETERMINED

30 Apr 2018

BRIEF-Karo Pharma Q1 EBITDA rose to SEK 89 mln

* KARO PHARMA DOUBLES SALES AND EARNINGS IN THE FIRST QUARTER

26 Apr 2018

BRIEF-Karo Pharma: Board Of Directors Resolves On Fully Guaranteed Rights Issue

* THE BOARD OF DIRECTORS OF KARO PHARMA HAS RESOLVED ON A FULLY GUARANTEED RIGHTS ISSUE SUBJECT TO APPROVAL BY THE ANNUAL GENERAL MEETING

04 Apr 2018

BRIEF-Karo Pharma Intends To Propose Dividend Of SEK 0.30 Per Share

* INTENDS TO PROPOSE DIVIDEND OF SEK 0.30 PER SHARE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

03 Apr 2018

BRIEF-Karo Pharma Acquires Major Product Portfolio for EUR 260 Mln

* ‍ACQUIRES A PRODUCT PORTFOLIO FROM DANISH PHARMACEUTICAL COMPANY LEO PHARMA A/S FOR 260 MEURO​

01 Mar 2018

BRIEF-Karo Pharma AB Q4 Adjusted EBITDA Rises To SEK 41.8 Mln

* Q4 NET SALES SEK 238.7 MILLION VERSUS SEK 96.5 MILLION YEAR AGO

22 Feb 2018

Earnings vs. Estimates